company background image
ELTP

Elite Pharmaceuticals OTCPK:ELTP Stock Report

Last Price

US$0.036

Market Cap

US$37.0m

7D

-3.9%

1Y

3.0%

Updated

28 Nov, 2022

Data

Company Financials
ELTP fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance3/6
Financial Health5/6
Dividends0/6

ELTP Stock Overview

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and manufacture of oral, controlled-release products and generic pharmaceuticals.

Elite Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Elite Pharmaceuticals
Historical stock prices
Current Share PriceUS$0.036
52 Week HighUS$0.052
52 Week LowUS$0.023
Beta0.37
1 Month Change9.24%
3 Month Change-2.30%
1 Year Change3.00%
3 Year Change-58.52%
5 Year Change-59.94%
Change since IPO-98.20%

Recent News & Updates

Recent updates

Shareholder Returns

ELTPUS PharmaceuticalsUS Market
7D-3.9%1.5%0.3%
1Y3.0%12.2%-20.5%

Return vs Industry: ELTP underperformed the US Pharmaceuticals industry which returned 9.9% over the past year.

Return vs Market: ELTP exceeded the US Market which returned -18.5% over the past year.

Price Volatility

Is ELTP's price volatile compared to industry and market?
ELTP volatility
ELTP Average Weekly Movement8.8%
Pharmaceuticals Industry Average Movement10.8%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: ELTP is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: ELTP's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199743Nasrat Hakimhttps://www.elitepharma.com

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and manufacture of oral, controlled-release products and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Products and New Drug Applications for Branded Products. It owns, licenses, and contract manufactures various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases.

Elite Pharmaceuticals, Inc. Fundamentals Summary

How do Elite Pharmaceuticals's earnings and revenue compare to its market cap?
ELTP fundamental statistics
Market CapUS$37.01m
Earnings (TTM)US$6.53m
Revenue (TTM)US$32.91m

5.6x

P/E Ratio

1.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ELTP income statement (TTM)
RevenueUS$32.91m
Cost of RevenueUS$17.65m
Gross ProfitUS$15.26m
Other ExpensesUS$8.72m
EarningsUS$6.53m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.0064
Gross Margin46.36%
Net Profit Margin19.85%
Debt/Equity Ratio59.0%

How did ELTP perform over the long term?

See historical performance and comparison